<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of botulinum toxin for cosmetic indications
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of botulinum toxin for cosmetic indications
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of botulinum toxin for cosmetic indications
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jean Carruthers, MD, FRCSC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey S Dover, MD, FRCPC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 08, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H24777424">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Botulinum toxin is an injectable neuromodulator derived from neurotoxins produced by
         <em>
          Clostridium botulinum
         </em>
         , the bacterium responsible for botulism. Through the inhibition of neurotransmission between peripheral nerve endings and muscle fibers, botulinum toxin weakens or paralyzes skeletal muscle. Initially used for medical indications, botulinum toxin injection has now become one of the most requested procedures in facial rejuvenation.
        </p>
        <p>
         When used appropriately, botulinum toxin injection is an overwhelmingly safe method for improving cosmetic defects that are caused by or exacerbated by muscle contraction, such as prominent glabellar rhytides. The effects of botulinum toxin are transient; muscular function typically returns to baseline within a few months.
        </p>
        <p>
         The mechanism of action, formulations, clinical use, and safety of botulinum toxin injections for cosmetic indications will be reviewed here. The use of botulinum toxin for specific cosmetic or medical indications is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16222.html" rel="external">
          "Botulinum toxin for cosmetic indications: Treatment of specific sites"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">
          "Treatment of dystonia in children and adults", section on 'Botulinum toxin injections'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4888.html" rel="external">
          "Treatment of myoclonus", section on 'Segmental or peripheral myoclonus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24777431">
         <span class="h1">
          DISCOVERY AND DEVELOPMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical relevance of
         <em>
          C. botulinum
         </em>
         , a gram-positive bacillus, was first recognized in 1897, when the toxin produced by the organism was identified as the etiologic agent of botulism [
         <a href="#rid1">
          1,2
         </a>
         ]. Since then, seven serotypes of botulinum toxin (A, B, C1, D, E, F, and G) produced by different strains of the bacterium have been identified. The pharmacologic properties of the serotypes differ, and only serotypes A and B are available for clinical use [
         <a href="#rid3">
          3-5
         </a>
         ]. Botulinum toxin type A is the most common form of botulinum toxin used in aesthetic clinical practice.
        </p>
        <p>
         The clinical utility of botulinum toxin initially became evident in the treatment of strabismus [
         <a href="#rid6">
          6
         </a>
         ]. Subsequently, botulinum toxin has been utilized for a variety of other medical conditions characterized by muscular hyperactivity, including blepharospasm [
         <a href="#rid7">
          7
         </a>
         ], hemifacial spasm [
         <a href="#rid8">
          8,9
         </a>
         ], and cervical dystonia [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">
          "Treatment of dystonia in children and adults", section on 'Focal dystonia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4888.html" rel="external">
          "Treatment of myoclonus", section on 'Segmental or peripheral myoclonus'
         </a>
         .)
        </p>
        <p>
         In 1992, we published the first report of the use of botulinum toxin for a cosmetic indication. This report documented the benefit of botulinum toxin type A for the treatment of glabellar frown lines [
         <a href="#rid11">
          11
         </a>
         ]. Botulinum toxin is now utilized for multiple cosmetic concerns that can be improved with local muscle relaxation, such as other dynamic rhytides on the upper face and skin lines located on the lower face and neck [
         <a href="#rid12">
          12-18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4082356">
         <span class="h1">
          MECHANISM OF ACTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical utility of botulinum toxin stems from the ability of the toxin to prevent muscular contraction through inhibiting the release of acetylcholine from peripheral nerve cells into neuromuscular junctions [
         <a href="#rid19">
          19
         </a>
         ]. Botulinum toxins are peptides that are composed of one heavy chain and one light chain. After the heavy chain of the injected toxin binds to receptors on the terminal ends of nerve cells, the peptide enters the cytoplasm through endocytosis. Once in the cytoplasm, the light chain cleaves components of SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor), a complex of proteins necessary for the exocytosis of acetylcholine. The sites of cleavage within the SNARE protein complex differ among the serotypes; while botulinum toxin types A, C1, and E cleave SNAP-25 (synaptosome-associated protein of 25 kd), serotypes B, D, F, and G cleave VAMP (vesicle-associated membrane protein). VAMP is also known as synaptobrevin.
        </p>
        <p>
         As a result of this cleavage, acetylcholine remains in the neuron, where it is unable to bind to receptors on muscle fibers and stimulate muscle contraction (chemodenervation). The inhibitory effect of botulinum toxin is temporary; recovery of muscular function often becomes clinically evident approximately three months after treatment as the neuromuscular junction begins to recover. The development of new collateral nerve ends may be partially responsible for recovery; however, these terminal buds appear to be transient, and recovery of the original nerve terminal eventually occurs [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24777445">
         <span class="h1">
          FORMULATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two serotypes of botulinum toxin have been formulated for clinical use, including botulinum toxin type A (the most common serotype used for cosmetic applications) and botulinum toxin type B. In order to prevent confusion between products, in 2009, the US Food and Drug Administration (FDA) recommended the use of specific names, rather than serotypes, to refer to the available formulations of botulinum toxin [
         <a href="#rid21">
          21
         </a>
         ]. Commercially available formulations of botulinum toxin type A in North America include
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         , and
         <a class="drug drug_general" data-topicid="120299" href="/z/d/drug information/120299.html" rel="external">
          prabotulinumtoxinA
         </a>
         [
         <a href="#rid19">
          19
         </a>
         ]. Commercial availability of
         <a class="drug drug_general" data-topicid="139586" href="/z/d/drug information/139586.html" rel="external">
          daxibotulinumtoxinA
         </a>
         is pending.
         <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">
          RimabotulinumtoxinB
         </a>
         is the established name for botulinum toxin type B.
        </p>
        <p class="headingAnchor" id="H4081645">
         <span class="h2">
          OnabotulinumtoxinA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Of the formulations of botulinum toxin type A that are available or in development,
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         (Botox, Botox Cosmetic, Vistabel, Vistabex) has been studied most extensively. OnabotulinumtoxinA is supplied as a preservative-free, vacuum-dried powder that contains the
         <em>
          C. botulinum
         </em>
         type A neurotoxin complex (50 or 100 units per vial) plus human albumin and sodium chloride. The FDA has approved onabotulinumtoxinA for the treatment of glabellar rhytides, lateral canthal lines (crow's feet), and forehead lines, but the toxin also is widely used for the treatment of other skin lines and for facial contouring [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4081652">
         <span class="h2">
          AbobotulinumtoxinA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initially marketed in Europe,
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         (Dysport) is another formulation of botulinum toxin type A utilized for cosmetic therapy. AbobotulinumtoxinA is supplied in vials that contain 300 or 500 units of lyophilized abobotulinumtoxinA plus serum albumin and lactose. AbobotulinumtoxinA became commercially available in North America in 2009 and has FDA approval for the treatment of glabellar lines.
        </p>
        <p class="headingAnchor" id="H4081673">
         <span class="h2">
          IncobotulinumtoxinA
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          IncobotulinumtoxinA
         </a>
         (Xeomin or Bocouture), a newer formulation of botulinum toxin type A, is approved for medical use and for injection of glabellar lines in multiple countries, including the United States. IncobotulinumtoxinA is supplied as a lyophilized powder that contains botulinum toxin A (50 or 100 units), human albumin, and sucrose. IncobotulinumtoxinA is free of complexing proteins, which some authors believe may result in a reduced risk of sensitization and antibody formation against the toxin [
         <a href="#rid23">
          23,24
         </a>
         ]. (See
         <a class="local">
          'Immunogenicity'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1867479295">
         <span class="h2">
          PrabotulinumtoxinA
         </span>
         <span class="headingEndMark">
          —
         </span>
         In 2019, the FDA approved prabotulinumtoxinA-xvfs (Jeuveau) for the treatment of moderate to severe glabellar lines in adults.
         <a class="drug drug_general" data-topicid="120299" href="/z/d/drug information/120299.html" rel="external">
          PrabotulinumtoxinA
         </a>
         is supplied as a vacuum-dried powder in a single-dose vial containing 100 units.
        </p>
        <p class="headingAnchor" id="H2958831215">
         <span class="h2">
          DaxibotulinumtoxinA
         </span>
         <span class="headingEndMark">
          —
         </span>
         In 2022, the FDA approved
         <a class="drug drug_general" data-topicid="139586" href="/z/d/drug information/139586.html" rel="external">
          daxibotulinumtoxinA
         </a>
         (Daxxify) for the temporary improvement in the appearance of moderate to severe glabellar lines in adults [
         <a href="#rid25">
          25
         </a>
         ]. The drug is supplied in vials containing 50 or 100 units of daxibotulinumtoxinA sterile lyophilized powder. Commercial availability is pending.
        </p>
        <p class="headingAnchor" id="H714881">
         <span class="h2">
          RimabotulinumtoxinB
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">
          RimabotulinumtoxinB
         </a>
         is commercially available as Myobloc or NeuroBloc. Myobloc, which is distributed in the United States, Canada, and Korea, is supplied in liquid form in vials that contain 5000 units of botulinum toxin type B per milliliter plus human serum albumin, sodium succinate, and sodium chloride. It is the primary agent used for the treatment of cervical dystonia, and compared to botulinum toxin type A, has been less studied for cosmetic indications. However, rimabotulinumtoxinB has been used successfully for the treatment of facial rhytides [
         <a href="#rid26">
          26-29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H714960">
         <span class="h2">
          Topical botulinum toxin A
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical formulations of botulinum toxin type A may have promise for the treatment of dynamic rhytides [
         <a href="#rid30">
          30-32
         </a>
         ]. In a randomized trial of 36 adults with moderate to severe lateral canthal lines, two 30-minute applications of a gel containing botulinum toxin type A separated by four weeks were superior to placebo for treatment [
         <a href="#rid30">
          30
         </a>
         ]. Additional studies are necessary to determine the role of topical botulinum toxin for cosmetic indications.
        </p>
        <p class="headingAnchor" id="H715017">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other botulinum toxin products available or in development include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chinese botulinum toxin A (CBTX-A)
         </strong>
         – Available in China, marketed as Prosigne in Brazil
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuronox
         </strong>
         – A formulation of botulinum toxin type A widely used in Korea and Southeast Asia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Botulinum toxin E (EB-001)
         </strong>
         – A formulation under development that may have a relatively fast onset and short duration of effect [
         <a href="#rid33">
          33
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24777452">
         <span class="h1">
          COSMETIC USE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since 1992, botulinum toxin has been used cosmetically in a number of clinical settings, ranging from the simple treatment of facial lines to more advanced facial sculpting. Examples of conditions that have been treated successfully with botulinum toxin include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glabellar rhytides (
         <a class="graphic graphic_picture graphicRef71122" href="/z/d/graphic/71122.html" rel="external">
          picture 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Horizontal lines on the forehead (
         <a class="graphic graphic_picture graphicRef50165" href="/z/d/graphic/50165.html" rel="external">
          picture 2
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lateral canthal lines (crow's feet) (
         <a class="graphic graphic_picture graphicRef59956" href="/z/d/graphic/59956.html" rel="external">
          picture 3
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depressed brow (
         <a class="graphic graphic_picture graphicRef71706" href="/z/d/graphic/71706.html" rel="external">
          picture 4
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertrophic orbicularis oculi muscle (small palpebral aperture)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rhytides from upper nasalis muscle contraction (bunny lines) (
         <a class="graphic graphic_picture graphicRef52791 graphicRef64576" href="/z/d/graphic/52791.html" rel="external">
          picture 5A-B
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nostril flare
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drooping nasal tip
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nasolabial folds (selected patients) (
         <a class="graphic graphic_picture graphicRef77905" href="/z/d/graphic/77905.html" rel="external">
          picture 6
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vertical perioral rhytides (
         <a class="graphic graphic_picture graphicRef50746" href="/z/d/graphic/50746.html" rel="external">
          picture 7
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mouth frown (
         <a class="graphic graphic_picture graphicRef76339" href="/z/d/graphic/76339.html" rel="external">
          picture 8
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gummy smile
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Melomental folds (marionette lines) (
         <a class="graphic graphic_picture graphicRef55290" href="/z/d/graphic/55290.html" rel="external">
          picture 9
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mental crease (horizontal crease on the chin) (
         <a class="graphic graphic_picture graphicRef80633" href="/z/d/graphic/80633.html" rel="external">
          picture 10
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peau d'orange chin (
         <a class="graphic graphic_picture graphicRef76750" href="/z/d/graphic/76750.html" rel="external">
          picture 11
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Masseteric hypertrophy (square jaw)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Horizontal neck lines (
         <a class="graphic graphic_picture graphicRef69540" href="/z/d/graphic/69540.html" rel="external">
          picture 12
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Platysmal bands on the neck (
         <a class="graphic graphic_picture graphicRef64918" href="/z/d/graphic/64918.html" rel="external">
          picture 13
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The approach to the treatment of specific clinical features with botulinum toxin is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/16222.html" rel="external">
          "Botulinum toxin for cosmetic indications: Treatment of specific sites"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1493518">
         <span class="h2">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, the clinical effects of botulinum toxin begin to appear in one to three days, peak in one to four weeks, and gradually decline after three to four months [
         <a href="#rid12">
          12
         </a>
         ]. However, the duration of response is dependent upon the injection site, dose, and specific formulation of botulinum toxin utilized [
         <a href="#rid34">
          34
         </a>
         ]. Some patients, particularly those who have received repeated injections in the same area, may experience benefits for six months or longer. This may be at least partially due to the development of muscle atrophy [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1493526">
         <span class="h3">
          OnabotulinumtoxinA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The results of multiple randomized trials support the efficacy of
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         for the treatment of dynamic rhytides [
         <a href="#rid36">
          36-41
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized, 120-day trial of 264 patients with moderate to severe glabellar lines found that treatment with 20 units of
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         was superior to placebo at all study time points [
         <a href="#rid36">
          36
         </a>
         ]. By day seven, glabellar line severity at maximum frown was scored as absent or mild in 167 out of 203 patients treated with botulinum toxin compared with 3 out of 61 patients treated with placebo (82 versus 5 percent). Similar results were noted at 30 days, but treatment effect was substantially reduced by day 120 (26 versus 0 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar findings were noted in a second placebo-controlled randomized trial that used a similar protocol in 273 patients with moderate to severe glabellar lines [
         <a href="#rid37">
          37
         </a>
         ]. Glabellar line severity at maximum frown was much more likely to be mild or absent at 30 days after treatment with
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         (77 versus 7 percent), but the amount of benefit was reduced at 120 days (24 versus 3 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized dose-response trial of
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         for moderate or severe crow's feet in 162 patients, all doses of onabotulinumtoxinA were superior to placebo for improvement in rhytid severity [
         <a href="#rid38">
          38
         </a>
         ]. Thirty days after treatment, improvement was detected in 85, 87, 52, 46, and 16 percent of patients who received bilateral injections of botulinum toxin (18 units, 12 units, 6 units, or 3 units) or placebo, respectively. Higher doses of onabotulinumtoxinA were associated with a longer duration of action and a greater magnitude of effect.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H138158090">
         <span class="h3">
          AbobotulinumtoxinA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The efficacy of
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         for dynamic rhytides is supported by randomized trials [
         <a href="#rid42">
          42-44
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a phase 3 randomized trial that investigated the efficacy of 50 units of
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         for the treatment of moderate to severe glabellar lines in 158 patients, treatment with abobotulinumtoxinA was superior to placebo [
         <a href="#rid43">
          43
         </a>
         ]. Glabellar line severity at maximum frown was much more likely to be mild or absent at 30 days with abobotulinumtoxinA (90 versus 8 percent). A significant difference in effect between treatment and placebo remained at day 120, but was no longer statistically significant by day 150.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar findings were noted in a second phase 3 randomized trial in which 816 patients were randomly assigned to receive 50 to 80 units of
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         (dose based upon muscle mass) or placebo [
         <a href="#rid44">
          44
         </a>
         ]. Glabellar line severity at maximum frown was much more likely to be mild or absent at 30 days (85 versus 3 percent). The median duration of treatment effect in the botulinum toxin group was 109 days.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H715028">
         <span class="h3">
          IncobotulinumtoxinA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The efficacy of
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         was investigated in two unpublished randomized trials in which patients with moderate to severe glabellar lines at maximum frown were treated with either 20 units of incobotulinumtoxinA (n = 366) or placebo (n = 181) [
         <a href="#rid45">
          45
         </a>
         ]. Successful treatment was defined as improvement from severe lines to mild or absent lines or from moderate lines to absent lines. Thirty days after injection, 77 and 71 percent of patients treated with incobotulinumtoxinA achieved treatment success compared with none of the patients treated with placebo.
        </p>
        <p class="headingAnchor" id="H1493637">
         <span class="h3">
          RimabotulinumtoxinB
         </span>
         <span class="headingEndMark">
          —
         </span>
         The efficacy of
         <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">
          rimabotulinumtoxinB
         </a>
         for dynamic wrinkles has been supported by the results of randomized trials and open-label studies [
         <a href="#rid26">
          26,29,46-48
         </a>
         ]. RimabotulinumtoxinB also may be useful for patients who fail to respond to botulinum toxin type A. RimabotulinumtoxinB was effective in an open-label study of 20 women with vertical glabellar rhytides that were refractory to or had a diminishing response to
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2379341482">
         <span class="h3">
          PrabotulinumtoxinA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Efficacy of
         <a class="drug drug_general" data-topicid="120299" href="/z/d/drug information/120299.html" rel="external">
          prabotulinumtoxinA
         </a>
         for glabellar lines has been demonstrated in randomized trials. In two identical phase 3 trials (n = 330 and n = 324), adults with moderate to severe glabellar lines were randomly assigned in a 3:1 ratio to receive either 20 units of prabotulinumtoxinA or placebo [
         <a href="#rid49">
          49
         </a>
         ]. At day 30, 68 and 70 percent of patients in the prabotulinumtoxinA groups achieved at least a two-point improvement on a four-point glabellar line severity scale compared with 1 percent of patients in the placebo groups.
        </p>
        <p class="headingAnchor" id="H522748678">
         <span class="h3">
          DaxibotulinumtoxinA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two placebo-controlled, phase 3, randomized trials (SAKURA 1 and SAKURA 2) support efficacy of
         <a class="drug drug_general" data-topicid="139586" href="/z/d/drug information/139586.html" rel="external">
          daxibotulinumtoxinA
         </a>
         for glabellar lines [
         <a href="#rid50">
          50
         </a>
         ]. In SAKURA 1 (n = 303), patients who received daxibotulinumtoxinA were more likely to achieve at least a two-point improvement in glabellar line severity at maximum frown at week 4 than patients in the placebo group (74 versus 0 percent). Similarly, in SAKURA 2 (n = 306), 74 percent of patients in the daxibotulinumtoxinA group and 1 percent of patients in the placebo group achieved this endpoint. The SAKURA 1 and SAKURA 2 trials suggested prolonged response as a benefit of daxibotulinumtoxinA; the median durations of response in the two trials were 28 and 26 weeks, respectively.
        </p>
        <p class="headingAnchor" id="H1420443">
         <span class="h3">
          Comparative efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Few randomized trials have directly compared different formulations of botulinum toxin for cosmetic indications. The results of small randomized trials suggest the following differences among the agents [
         <a href="#rid48">
          48,51-53
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The onset of action of
         <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">
          rimabotulinumtoxinB
         </a>
         appears to be faster than that of
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         [
         <a href="#rid48">
          48,51,53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          OnabotulinumtoxinA
         </a>
         provides longer duration of efficacy than
         <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">
          rimabotulinumtoxinB
         </a>
         [
         <a href="#rid51">
          51,53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pain with injection is less with
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         than with
         <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">
          rimabotulinumtoxinB
         </a>
         [
         <a href="#rid51">
          51
         </a>
         ]. The increased pain associated with injection of rimabotulinumtoxinB is thought to be related to its acidic pH (pH = 5.6), a property necessary for the product to remain stable in solution. Dilution of rimabotulinumtoxinB with preserved
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         appears to decrease the pain associated with injection [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Additional studies are necessary to confirm these findings. Dose conversions among the formulations are not standardized, and it is conceivable that studies utilizing different doses of these agents might find conflicting results. As an example, the duration of action of botulinum toxin is dose-dependent. In a randomized trial that compared two different doses of
         <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">
          rimabotulinumtoxinB
         </a>
         , the duration of efficacy was longer with the higher dose (10 to 12 weeks versus 6 to 8 weeks) [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         Based upon studies in patients with hyperhidrosis and cervical dystonia, it has been proposed that
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         may diffuse more extensively within tissue than
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         , which may contribute to a higher incidence of adverse effects [
         <a href="#rid55">
          55-58
         </a>
         ]. However, additional studies are necessary to confirm whether these findings are applicable to cosmetic use [
         <a href="#rid59">
          59,60
         </a>
         ].
        </p>
        <p>
         Studies suggest that
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         and
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         have similar levels of clinical potency, safety, and duration of effect when used for medical indications [
         <a href="#rid23">
          23,61-65
         </a>
         ], and randomized trials have compared the efficacy of incobotulinumtoxinA and onabotulinumtoxinA for cosmetic use. In a 12-week trial comparing treatment of moderate to severe glabellar lines with incobotulinumtoxinA (n = 284) versus onabotulinumtoxinA (n = 97), the two agents were similarly effective [
         <a href="#rid66">
          66
         </a>
         ]. In addition, an intraindividual trial with 12 patients found similar efficacy between these agents in the treatment of periorbital rhytides [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
         Randomized trials support comparable efficacy of
         <a class="drug drug_general" data-topicid="120299" href="/z/d/drug information/120299.html" rel="external">
          prabotulinumtoxinA
         </a>
         and
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         for glabellar lines and crow's feet [
         <a href="#rid68">
          68,69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H522661">
         <span class="h2">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Absolute contraindications to botulinum toxin injection include infection at the site of injection or known hypersensitivity to any component of the product.
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          AbobotulinumtoxinA
         </a>
         should
         <strong>
          not
         </strong>
         be given to patients with allergies to cow's milk protein; this limitation does not apply to
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         , or
         <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">
          rimabotulinumtoxinB
         </a>
         .
        </p>
        <p>
         Relative contraindications to treatment include neuromuscular disorders that could amplify the effect of the toxin, such as myasthenia gravis, Eaton-Lambert syndrome, myopathies, or amyotrophic lateral sclerosis. Caution should also be exercised in patients taking drugs that can interfere with neuromuscular transmission (eg, aminoglycosides, cholinesterase inhibitors,
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         , and curare-type nondepolarizing blockers) [
         <a href="#rid70">
          70,71
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          OnabotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         , and
         <a class="drug drug_general" data-topicid="9155" href="/z/d/drug information/9155.html" rel="external">
          rimabotulinumtoxinB
         </a>
         injection generally should be
         <strong>
          avoided
         </strong>
         in pregnant women. A similar approach is taken for
         <a class="drug drug_general" data-topicid="120299" href="/z/d/drug information/120299.html" rel="external">
          prabotulinumtoxinA
         </a>
         , given that data are considered insufficient to confirm the level of risk of adverse developmental outcomes [
         <a href="#rid72">
          72
         </a>
         ]. The risks of maternal-infant transmission of botulinum toxin in lactating women are unknown; thus, we avoid their use in this population.
        </p>
        <p class="headingAnchor" id="H1493835">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Familiarity with facial anatomy and facial muscle function is essential for proper technique (
         <a class="graphic graphic_figure graphicRef58011" href="/z/d/graphic/58011.html" rel="external">
          figure 1
         </a>
         ). Improper injection can result in cosmetically unfavorable results or functional disability. For example, botulinum toxin injection for horizontal forehead lines may result in unsightly lowering of the brow if the frontalis muscle is excessively weakened. (See
         <a class="local">
          'Complications'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H25308474">
         <span class="h2">
          Preparing for treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to treatment, the clinician should determine whether the patient's concerns are appropriate for treatment with botulinum toxin. Botulinum toxin is effective for aesthetic concerns that are caused by underlying muscle contraction. Individuals with other signs of aging, such as lentigines, telangiectasias, textural changes, and skin laxity often require additional cosmetic procedures to achieve satisfactory rejuvenation. (See
         <a class="local">
          'Use as adjunctive therapy'
         </a>
         below.)
        </p>
        <p>
         If the cosmetic defect can be improved with botulinum toxin, and patient characteristics do not indicate that treatment is contraindicated, the patient should then be thoroughly informed about the expected duration of treatment benefit, the need for retreatment, and the potential adverse effects of botulinum toxin injection. Patients who have unrealistic expectations for treatment results are likely to remain dissatisfied regardless of the clinical outcome. We have found that digital photographs, taken both before and after treatment are useful for assessing improvement. (See
         <a class="local">
          'Side effects and complications'
         </a>
         below.)
        </p>
        <p>
         Because botulinum toxin weakens or paralyzes muscles, the effect of injections on other bodily functions also must be considered. For example, singers or individuals who play wind instruments are not always good candidates for perioral injections.
        </p>
        <p class="headingAnchor" id="H1730154">
         <span class="h3">
          Reconstitution
         </span>
         <span class="headingEndMark">
          —
         </span>
         Botulinum toxin A must be reconstituted in
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         prior to use. Preferred dilution volumes vary widely among clinicians. Package inserts suggest use of the following dilutions when treating glabellar lines: 20 units of
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         , or
         <a class="drug drug_general" data-topicid="120299" href="/z/d/drug information/120299.html" rel="external">
          prabotulinumtoxinA
         </a>
         and 50 units of
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          OnabotulinumtoxinA
         </strong>
         <strong>
          and
         </strong>
         <strong>
          incobotulinumtoxinA
         </strong>
         <strong>
         </strong>
         – 2.5 mL of sterile 0.9% sodium chloride added to the 100 unit vial or 1.25 mL of 0.9% sodium chloride to the 50 unit vial. Both dilutions result in a dose of 4 units/0.1 mL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          PrabotulinumtoxinA
         </strong>
         – 2.5 mL of 0.9% sodium chloride added to a 100 unit vial. The resulting dose is 4 units per 0.1 mL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AbobotulinumtoxinA
         </strong>
         <strong>
         </strong>
         – 2.5 mL or 1.5 mL of 0.9% sodium chloride added to the 300 unit vial. This results in doses of 10 units/0.08 mL and 10 units/0.05 mL, respectively.
        </p>
        <p>
        </p>
        <p>
         We often prefer to use smaller dilution volumes to allow more precise administration of the toxin. In our experience, this appears to improve the duration of effect and reduce the risk of side effects secondary to excessive spread of the toxin to adjacent tissues [
         <a href="#rid73">
          73
         </a>
         ]. We customarily utilize concentrations 100 units/mL of
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         in our practice. The use of larger dilution volumes may be beneficial in settings in which treatment of large areas is desired [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         Unpreserved
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         is the diluent recommended by the manufacturers of
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         , and
         <a class="drug drug_general" data-topicid="120299" href="/z/d/drug information/120299.html" rel="external">
          prabotulinumtoxinA
         </a>
         ; however, in clinical practice, many clinicians in North America reconstitute these products in saline containing benzyl alcohol to reduce the pain associated with injection [
         <a href="#rid75">
          75
         </a>
         ]. In a small randomized trial in which patients with dynamic rhytides on the upper face were treated with onabotulinumtoxinA in either preservative-containing or preservative-free saline, use of preserved saline reduced patient discomfort and did not alter treatment efficacy [
         <a href="#rid76">
          76
         </a>
         ]. Similar findings were observed in a small randomized trial with abobotulinumtoxinA [
         <a href="#rid77">
          77
         </a>
         ]. The possibility of allergy to benzyl alcohol must be considered when using preserved saline for reconstitution.
        </p>
        <p>
         Opinion varies on the delayed use of botulinum toxin after reconstitution [
         <a href="#rid75">
          75
         </a>
         ]. Although the package inserts for
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         , and
         <a class="drug drug_general" data-topicid="120299" href="/z/d/drug information/120299.html" rel="external">
          prabotulinumtoxinA
         </a>
         recommend refrigerating these products at 2 to 8°C and then discarding them if they are not used within 24 or 4 hours after reconstitution, respectively, many clinicians refrigerate reconstituted vials for longer periods of time in anticipation of future use. One randomized trial in which 85 patients were treated with onabotulinumtoxinA that was reconstituted in preservative-free 0.9%
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         and refrigerated at 4°C for periods of time ranging from one day to six weeks found no significant difference in efficacy among solutions of different ages [
         <a href="#rid78">
          78
         </a>
         ]. In addition, other randomized trials have documented retained treatment efficacy with botulinum toxin type A reconstituted one to two weeks prior to use [
         <a href="#rid79">
          79-81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H691466002">
         <span class="h3">
          Dose conversion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dose conversions among the formulations of botulinum toxin A are not standardized. The results of a systematic review and subsequent randomized trials suggest that
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         :
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         dose ratios lower than 3:1 (eg, 2:1 or 2.5:1) are appropriate [
         <a href="#rid82">
          82-84
         </a>
         ]. We typically utilize a dose ratio of 2.5:1 when transitioning between these products. In clinical practice,
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         , onabotulinumtoxinA, and
         <a class="drug drug_general" data-topicid="120299" href="/z/d/drug information/120299.html" rel="external">
          prabotulinumtoxinA
         </a>
         are administered in a 1:1 ratio; however, further study is necessary to determine whether this conversion is accurate [
         <a href="#rid85">
          85,86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1730226">
         <span class="h3">
          Pain and bruising
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pain from injection is well-tolerated by many patients. In addition to the use of preserved
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , pain from injection can be minimized with application of ice to the treatment site prior to treatment or the use of topical anesthetic agents or vibrational anesthesia.
        </p>
        <p>
         Bruising is most likely to occur after periorbital and perioral injections. Avoidance of inhibitors of platelet function for 7 to 10 days prior to periorbital injection (eg,
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">
          vitamin E
         </a>
         , alcohol) is preferable in patients who can discontinue these agents safely.
        </p>
        <p class="headingAnchor" id="H25308481">
         <span class="h2">
          During treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         A small-volume (eg, 0.3 mL) insulin syringe with a small-diameter needle is typically used for injection. An impact of needle diameter on patient discomfort was found in a randomized trial (n = 20) that compared the pain associated with injection of
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         with a 30-gauge needle into one side of the forehead to injection with a 32-gauge needle on the contralateral side [
         <a href="#rid87">
          87
         </a>
         ]. Clinically significant pain was more likely to occur with 30-gauge needles (40 percent of patients) than with 32-gauge needles (15 percent of patients; odds ratio 3.80, 95% CI 1.05-13.78), suggesting that patients who experience significant pain during facial injection may benefit from use of a smaller-gauge needle.
        </p>
        <p>
         In our practice, we typically use a 31-gauge needle for injection. Use of a syringe that lacks a needle hub will minimize product waste.
        </p>
        <p>
         The appropriate dose of botulinum toxin is determined by the treatment location and muscle mass; men typically have stronger and larger facial muscles and require higher doses than women. The number of injections and appropriate spacing of injections is dependent on the specific cosmetic defect. Local anatomic landmarks are used to guide the placement of injections.
        </p>
        <p>
         Many clinicians, including ourselves, sometimes massage the treatment site after injection in an attempt to spread the toxin, which theoretically could increase the efficacy of treatment. The benefit of this procedure has not been formally studied, and if performed, care should be taken to avoid massaging in a direction that could promote movement of the toxin to untargeted areas. We generally avoid massage for injection sites above the brow due to a concern for inducing brow ptosis. (See
         <a class="local">
          'Complications'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/16222.html" rel="external">
          "Botulinum toxin for cosmetic indications: Treatment of specific sites", section on 'Horizontal forehead rhytides'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25308488">
         <span class="h2">
          After treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         When treating the periorbital region, we apply gentle direct pressure immediately after withdrawal of the needle to reduce the occurrence of bruising.
        </p>
        <p>
         Although there is a lack of data to confirm the efficacy of these measures, we and many other clinicians instruct patients to engage in actions that theoretically may minimize excessive diffusion of the toxin to untargeted areas and improve the efficacy of treatment. To minimize excessive spread of the toxin, we instruct patients to remain upright for at least two to four hours after injection and recommend that they avoid pressing or rubbing the treated areas for 24 hours. We also tell patients to contract and relax the treated muscles as much as possible for two to three hours after the procedure. In theory, contracting muscles may facilitate uptake of the toxin by neurons, accelerating the appearance of clinical benefit [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         The manufacturers of
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         , and
         <a class="drug drug_general" data-topicid="120299" href="/z/d/drug information/120299.html" rel="external">
          prabotulinumtoxinA
         </a>
         recommend that treatments should be spaced by at least three months. However, for patients in whom the response to treatment is unpredictable (patients receiving an initial treatment or a dosing change), we schedule an appointment for reassessment two to three weeks after treatment. If the desired effect has not been achieved, we perform additional injections at that time to improve treatment results; subsequent injections are performed at longer intervals. In patients who have received large doses (eg, greater than 100 units of onabotulinumtoxinA), we wait one to two months before administering touch-up injections in an attempt to reduce the risk for immunogenicity. (See
         <a class="local">
          'Immunogenicity'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H24777599">
         <span class="h1">
          SIDE EFFECTS AND COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         When patients are appropriately selected and proper dosing and injection technique are utilized, the use of botulinum toxin for cosmetic indications appears to be relatively safe [
         <a href="#rid21">
          21,88
         </a>
         ]. Side effects are usually mild and transient and most commonly include swelling or bruising at the injection site, mild headache, or flu-like symptoms [
         <a href="#rid89">
          89
         </a>
         ]. Undesired impairment of muscle function may also occur, but is usually associated with poor injection technique or inappropriate patient selection. Because smaller doses are less likely to cause unintended adverse effects, a conservative approach to treatment is advisable.
        </p>
        <p class="headingAnchor" id="H525807">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffusion of botulinum toxin occasionally results in effects on muscles or glands adjacent to the targeted musculature. Diffusion of toxin in the upper face can result highly undesirable adverse effects that last for 2 to 12 weeks, including brow ptosis (excessive weakening of the frontalis muscle) and eyelid ptosis (weakening of the upper eyelid levator muscle secondary to diffusion into the orbital septum). In addition, a quizzical or "cockeyed" appearance ("Mr. Spock" eyebrow) can result from preferential weakening of the medial frontalis muscles, which allows unaffected lateral muscle fibers of the frontalis to elevate the lateral brow. Other adverse effects that can occur in the upper face include diplopia, ectropion, lower eyelid droop, epiphora (excessive tearing), decreased strength of eye closure, and dry eye [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         In the lower face, complications of treatment typically involve effects on muscle function and facial expression. These adverse effects usually are due to the use of excessive doses or injection into inappropriate locations. Flaccid cheek, incompetent mouth, asymmetrical smile, and loss of the ability to whistle are most likely to occur when injections are placed too close to the mouth, injections are performed in the mental fold, or when botulinum toxin interacts with the orbicularis oris muscle. The administration of high doses in the neck area can lead to dysphagia and weakness of the neck flexors.
        </p>
        <p>
         Eyelid ptosis can be partially improved with
         <a class="drug drug_general" data-topicid="8863" href="/z/d/drug information/8863.html" rel="external">
          apraclonidine
         </a>
         drops given two to three times per day until resolution. This usually results in 1 to 2 mm of eyelid elevation. The quizzical-appearing brow can be remedied through injection of the lateral frontalis musculature. Other functional adverse effects that cannot be improved with compensatory treatment resolve as the effect of botulinum toxin diminishes.
        </p>
        <p class="headingAnchor" id="H24777620">
         <span class="h2">
          Clinical safety record
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examination of the available data on botulinum toxin reveals an impressive safety record. The authors of a 2004 systematic review and meta-analysis of randomized trials (n = 1425) found no reports of serious adverse effects in patients treated with
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         for medical or cosmetic purposes [
         <a href="#rid90">
          90
         </a>
         ]. Serious adverse effects reported to the FDA have also been low in number; between 1989 and 2003, only 36 serious adverse effects associated with cosmetic use were reported. Examples of the serious adverse effects that were documented included injection site reactions, headache, focal facial paralysis, muscle weakness, flu-like symptoms, dysphagia, respiratory compromise, cardiac arrhythmia, seizure, ocular abnormalities, and allergic reactions. Of note, 13 of the patients who experienced serious adverse effects had underlying medical conditions that may have contributed to the observed event (eg, respiratory compromise in a patient with asthma and cardiac arrhythmia in a patient with a history of heart murmur).
        </p>
        <p>
         Although the risk of serious adverse effects is low with cosmetic use, side effects such as aspiration, dysphagia, pneumonia, anaphylaxis, botulism, and death have been reported in association with the use of botulinum toxin [
         <a href="#rid91">
          91-96
         </a>
         ]. As a result, in 2009, the US FDA instituted a requirement for boxed warnings on product labels and a Risk Evaluation and Mitigation Strategy (a consumer guide outlining the risks associated with treatment) for all botulinum toxin products [
         <a href="#rid97">
          97-99
         </a>
         ].
        </p>
        <p>
         Because the effect of botulinum toxin is temporary, patients require additional treatment to maintain improvement. The safety of repetitive treatment with botulinum toxin was evaluated in a retrospective study of more than 4000 treatments in 945 patients treated for lines in the upper face [
         <a href="#rid100">
          100
         </a>
         ]. Patients had to have received a minimum of three consecutive treatment cycles. Only mild to moderate adverse effects were detected; bruising and ptosis were most common. In addition, the incidence of side effects decreased with repeated injections, a finding that has been reported in studies of the medical use of botulinum toxin type A [
         <a href="#rid101">
          101,102
         </a>
         ]. Repeat injections with
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         have also been well tolerated in large open label studies [
         <a href="#rid103">
          103,104
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21137531">
         <span class="h2">
          Immunogenicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The commercially available preparations of
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         , and
         <a class="drug drug_general" data-topicid="120299" href="/z/d/drug information/120299.html" rel="external">
          prabotulinumtoxinA
         </a>
         are complexed with clostridial proteins, a characteristic that may have an effect on the immunogenicity of these agents [
         <a href="#rid12">
          12,105,106
         </a>
         ]. Although antibody formation against botulinum toxin has been linked to reduced treatment efficacy in some reports [
         <a href="#rid107">
          107-110
         </a>
         ], the occurrence of this phenomenon appears to be rare, particularly in patients treated for cosmetic indications [
         <a href="#rid111">
          111,112
         </a>
         ]. In a meta-analysis composed of randomized trials and open label studies published between 1999 and 2007, out of 2240 patients treated with onabotulinumtoxinA for a variety of indications (including 718 patients treated for glabellar lines), only 11 patients exhibited seroconversion. A lack of response to treatment followed conversion to seropositivity in only three patients, none of whom were treated for purely aesthetic indications [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
         Injecting the lowest effective doses, with the longest feasible intervals between injections, may minimize the potential for immunogenicity [
         <a href="#rid101">
          101,113
         </a>
         ]. Because
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         is free of complexing proteins, the immunogenicity of this product may be different from the previously available complexed products [
         <a href="#rid23">
          23,24,105
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4081882">
         <span class="h1">
          USE AS ADJUNCTIVE THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Botulinum toxin is highly effective in the treatment of dynamic rhytides. However, deeper rhytides and skin folds or other signs of skin aging are often best treated with botulinum toxin plus soft tissue augmentation, laser skin resurfacing, microfocused ultrasound, or surgical intervention [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4081889">
         <span class="h2">
          Soft-tissue augmentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of cosmetic fillers in conjunction with botulinum toxin can be of value, particularly when treating the brow, nasojugal folds, perioral region, and the neck [
         <a href="#rid115">
          115
         </a>
         ]. This technique may be particularly useful in patients who present for the treatment of deep rhytides that are evident at rest. (See
         <a class="medical medical_review" href="/z/d/html/16532.html" rel="external">
          "Injectable soft tissue fillers: Overview of clinical use"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16399.html" rel="external">
          "Injectable soft tissue fillers: Temporary agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13652.html" rel="external">
          "Injectable soft tissue fillers: Permanent agents"
         </a>
         .)
        </p>
        <p>
         When given one week prior to treatment with fillers, botulinum toxin decreases the dynamic component of the targeted rhytid, leading to increased longevity of the filling agent in tissue [
         <a href="#rid115">
          115-118
         </a>
         ]. In small randomized trials and a retrospective study, combination therapy with botulinum toxin A and cosmetic fillers has been associated superior efficacy and improved patient satisfaction compared to monotherapy with either procedure [
         <a href="#rid118">
          118-121
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4081896">
         <span class="h2">
          Lasers/light therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Traditional and fractional laser resurfacing are effective treatments for features of skin aging, including the treatment of rhytides. Impairment of muscle action with botulinum toxin before resurfacing may improve healing and collagen remodeling after laser treatment, contributing to improved aesthetic results [
         <a href="#rid117">
          117,122-124
         </a>
         ]. In addition, postoperative injections may prolong the results of laser resurfacing by reducing the rate of wrinkle recurrence [
         <a href="#rid122">
          122,125,126
         </a>
         ]. In one randomized bilateral comparison trial of 33 patients treated with periorbital injections of
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          onabotulinumtoxinA
         </a>
         or placebo prior to and after erbium:yttrium aluminum garnet (Er:YAG) laser resurfacing, greater improvement in rhytides, and other signs of photoaging were observed in sites treated with botulinum toxin [
         <a href="#rid127">
          127
         </a>
         ]. Postoperative onabotulinumtoxinA also prolonged the correction of dynamic rhytides in a placebo-controlled randomized bilateral comparison trial of 40 patients treated with carbon dioxide laser resurfacing [
         <a href="#rid126">
          126
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13629.html" rel="external">
          "Ablative laser resurfacing for skin rejuvenation", section on 'Approach to therapy'
         </a>
         .)
        </p>
        <p>
         The addition of botulinum toxin injections to the treatment of photoaging with intense pulsed light (IPL) was associated with increased overall aesthetic benefit in two small, randomized trials. Further studies are necessary to explore the effects of combination therapy with botulinum toxin and IPL.
        </p>
        <p class="headingAnchor" id="H2857140426">
         <span class="h2">
          Microfocused ultrasound with visualization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Microfocused ultrasound with visualization (MFU-V) involves the use of ultrasound energy to stimulate collagen remodeling through heating of dermal and subdermal tissues. This treatment results in tissue tightening and lifting without epidermal damage [
         <a href="#rid128">
          128
         </a>
         ]. If botulinum toxin injections and MFU-V are to be performed on the same area of skin on the same day, treating with MFU-V first followed by botulinum toxin has been suggested based upon the risk for contamination of multiuse ultrasound transducers and the potential risk for increased spread of the neurotoxin during MFU-V treatment [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
         In general, caution should be exercised when using neuromodulators after MFU-V treatments. The increased blood flow caused by the MFU-V treatment might increase spread of the neuromodulator and increase the risk of associated side effects.
        </p>
        <p class="headingAnchor" id="H4081903">
         <span class="h2">
          Surgery and wound healing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chemodenervation with botulinum toxin is a useful adjunct to many aesthetic surgeries. Treatment before and after surgical procedures can be of value for stabilizing musculature during healing, thereby reducing the risk for wound dehiscence and improving outcomes of surgical procedures for facial aging (eg, brow lifts, blepharoplasty, facelifts) [
         <a href="#rid117">
          117
         </a>
         ]. Moreover, pretreating the underlying musculature with botulinum toxin type A can allow for the use of finer sutures, contributing to improved aesthetic outcomes [
         <a href="#rid129">
          129-132
         </a>
         ]. Botulinum toxin also reduces tension on the wound edge, allowing for faster healing with less prominent scarring [
         <a href="#rid133">
          133,134
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H522914">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Botulinum toxin, the causative agent of botulism, is used clinically for a variety of indications. Through the controlled inhibition of local neurotransmission, botulinum toxin injections improve aesthetic concerns that are caused or exacerbated by muscular contraction. The effect of treatment is temporary; muscle recovery often becomes clinically evident a few months after treatment. (See
         <a class="local">
          'Mechanism of action'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serotypes
         </strong>
         – The mechanisms of action and clinical properties of botulinum toxin vary according to serotype. Botulinum toxin type A is the primary form of botulinum toxin utilized for cosmetic treatment. Botulinum toxin type B has been less extensively studied for cosmetic indications, but also appears to be effective in this setting. (See
         <a class="local">
          'Formulations'
         </a>
         above and
         <a class="local">
          'Cosmetic use'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formulations
         </strong>
         – Various formulations of botulinum toxin A are available worldwide.
         <a class="drug drug_general" data-topicid="9161" href="/z/d/drug information/9161.html" rel="external">
          OnabotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          abobotulinumtoxinA
         </a>
         ,
         <a class="drug drug_general" data-topicid="15586" href="/z/d/drug information/15586.html" rel="external">
          incobotulinumtoxinA
         </a>
         , and
         <a class="drug drug_general" data-topicid="120299" href="/z/d/drug information/120299.html" rel="external">
          prabotulinumtoxinA
         </a>
         are the formulations available for clinical use in North America. Few high-quality studies have directly compared the efficacy of different formulations of botulinum toxin. (See
         <a class="local">
          'Formulations'
         </a>
         above and
         <a class="local">
          'Cosmetic use'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications
         </strong>
         – Absolute contraindications to treatment with botulinum toxin include infection at the injection site and hypersensitivity to product components.
         <a class="drug drug_general" data-topicid="9195" href="/z/d/drug information/9195.html" rel="external">
          AbobotulinumtoxinA
         </a>
         should
         <strong>
          not
         </strong>
         be given to patients who are allergic to cow's milk protein. (See
         <a class="local">
          'Contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment principles
         </strong>
         – Careful patient selection and patient education, as well as thorough understanding of head and neck anatomy and appropriate injection technique are critical for the achievement of desired results and minimization of adverse effects. Common complications of botulinum toxin injection include transient swelling, bruising, and headache. When administered appropriately, serious adverse effects associated with the use of botulinum toxin for cosmetic indications are rare. (See
         <a class="local">
          'Treatment'
         </a>
         above and
         <a class="local">
          'Side effects and complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – Improper placement of injections or diffusion of the toxin to untargeted areas after injection can result in excessive muscle weakness that can cause temporary disfigurement or functional impairments. Some cosmetic defects such as eyelid ptosis and a quizzical-appearing brow can be improved with therapeutic interventions. In other cases, improvement is dependent upon the diminishing effect of botulinum toxin over time. (See
         <a class="local">
          'Side effects and complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use as adjunctive therapy
         </strong>
         – Botulinum toxin can be used in conjunction with other aesthetic procedures to improve clinical outcomes. Patients undergoing injection of cosmetic fillers, ablative laser resurfacing, microfocused ultrasound, or facial cosmetic surgeries may benefit from the concomitant use of botulinum toxin. (See
         <a class="local">
          'Use as adjunctive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1072391003">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Alastair Carruthers, FRCPC, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          DasGupta BR. Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In: Therapy with Botulinum Toxin, Jankovic J, Hallet M (Eds), Marcel Dekker, 1994. p.15.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schantz EJ, Johnson EA. Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med 1997; 40:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke GS. Notes on Bacillus botulinus. J Bacteriol 1919; 4:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001; 8 Suppl 5:21.
          </a>
         </li>
         <li class="breakAll">
          Dolly JO, Lisk G, Foran PG, et al. Insights into the extended duration of neuroparalysis by botulinum neurotoxin A relative to the other shorter-acting serotypes: differences between motor nerve terminals and cultured neurons. In: Scientific and Therapeutic Aspects of Botulinum Toxin, 1st ed, Brin MF, Jankovic J, Hallett M (Eds), Lippincott Williams &amp; Wilkins, 2002. p.91.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87:1044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wabbels B, Reichel G, Fulford-Smith A, et al. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm (Vienna) 2011; 118:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers J, Stubbs HA. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. Can J Neurol Sci 1987; 14:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borodic GE, Cheney M, McKenna M. Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry. Plast Reconstr Surg 1992; 90:972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsui JK, Eisen A, Mak E, et al. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 1985; 12:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 18:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers A, Carruthers J. Botulinum toxin type A: history and current cosmetic use in the upper face. Semin Cutan Med Surg 2001; 20:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers J, Carruthers A. Botulinum toxin A in the mid and lower face and neck. Dermatol Clin 2004; 22:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowe NJ, Yamauchi P. Cosmetic uses of botulinum toxins for lower aspects of the face and neck. Clin Dermatol 2004; 22:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dayan SH, Maas CS. Botulinum toxins for facial wrinkles: beyond glabellar lines. Facial Plast Surg Clin North Am 2007; 15:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fagien S, Carruthers JD. A comprehensive review of patient-reported satisfaction with botulinum toxin type a for aesthetic procedures. Plast Reconstr Surg 2008; 122:1915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers A, Carruthers J, Lei X, et al. OnabotulinumtoxinA treatment of mild glabellar lines in repose. Dermatol Surg 2010; 36 Suppl 4:2168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blitzer A, Brin MF, Keen MS, Aviv JE. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 1993; 119:1018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giordano CN, Matarasso SL, Ozog DM. Injectable and topical neurotoxins in dermatology: Basic science, anatomy, and therapeutic agents. J Am Acad Dermatol 2017; 76:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meunier FA, Schiavo G, Molgó J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 2002; 96:105.
          </a>
         </li>
         <li class="breakAll">
          www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175013.htm (Accessed on March 28, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers J, Carruthers A. The evolution of botulinum neurotoxin type A for cosmetic applications. J Cosmet Laser Ther 2007; 9:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 2007; 67:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 2010; 4:325.
          </a>
         </li>
         <li class="breakAll">
          Daxxify (daxibotulinumtoxinA-lanm) for injection, for intramuscular use. US FDA approved product information; Newark, CA: Revance Therapeutics, Inc; September. https://revance.com/wp-content/themes/allen-larson-theme/files/daxi-pi-and-med-guide.pdf (Accessed on October 19, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramirez AL, Reeck J, Maas CS. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg 2002; 126:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alster TS, Lupton JR. Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A. Dermatol Surg 2003; 29:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim EJ, Ramirez AL, Reeck JB, Maas CS. The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines. Plast Reconstr Surg 2003; 112:88S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadick NS. Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinkles. Dermatol Surg 2003; 29:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandt F, O'Connell C, Cazzaniga A, Waugh JM. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. Dermatol Surg 2010; 36 Suppl 4:2111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins A, Nasir A. Topical botulinum toxin. J Clin Aesthet Dermatol 2010; 3:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chajchir I, Modi P, Chajchir A. Novel topical BoNTA (CosmeTox, toxin type A) cream used to treat hyperfunctional wrinkles of the face, mouth, and neck. Aesthetic Plast Surg 2008; 32:715.
          </a>
         </li>
         <li class="breakAll">
          United States National Library of Medicine. Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines. https://clinicaltrials.gov/ct2/show/NCT02939326 (Accessed on April 21, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flynn TC. Botulinum toxin: examining duration of effect in facial aesthetic applications. Am J Clin Dermatol 2010; 11:183.
          </a>
         </li>
         <li class="breakAll">
          Murray C, Solish N. Botulinum toxin injections. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton, SE (Eds), Elsevier Inc, 2007. p.851.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers JD, Lowe NJ, Menter MA, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003; 112:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowe NJ, Ascher B, Heckmann M, et al. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005; 31:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grimes PE, Shabazz D. A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI. Dermatol Surg 2009; 35:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 2005; 31:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumann L, Dayan S, Connolly S, et al. Duration of Clinical Efficacy of OnabotulinumtoxinA in Crow's Feet Lines: Results from Two Multicenter, Randomized, Controlled Trials. Dermatol Surg 2016; 42:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin MG, Dover J, Glogau RG, et al. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol 2009; 8:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg 2009; 35:1893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kane MA, Brandt F, Rohrich RJ, et al. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg 2009; 124:1619.
          </a>
         </li>
         <li class="breakAll">
          Xeomin [package insert]. Greensboro, NC: Merz Pharmaceuticals, LLC; 2011.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers A, Carruthers J, Flynn TC, Leong MS. Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines. Dermatol Surg 2007; 33:S60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadick NS, Faacs . Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study. Dermatol Surg 2002; 28:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flynn TC, Clark RE 2nd. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 2003; 29:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beer KR, Shamban AT, Avelar RL, et al. Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies. Dermatol Surg 2019; 45:1381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg 2020; 145:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 2003; 29:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowe PL, Patnaik R, Lowe NJ. A comparison of two botulinum type a toxin preparations for the treatment of glabellar lines: double-blind, randomized, pilot study. Dermatol Surg 2005; 31:1651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowe NJ, Yamauchi PS, Lask GP, et al. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 2002; 4:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Laborde S, Dover JS, Moore M, et al. Reduction in injection pain with botulinum toxin type B further diluted using saline with preservative: a double-blind, randomized controlled trial. J Am Acad Dermatol 2003; 48:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 2003; 149:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trindade de Almeida AR, Marques E, de Almeida J, et al. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007; 33:S37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cliff SH, Judodihardjo H, Eltringham E. Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol 2008; 7:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pickett A, Dodd S, Rzany B. Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Cosmet Laser Ther 2008; 10:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kane M, Donofrio L, Ascher B, et al. Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations. J Drugs Dermatol 2010; 9:s7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dressler D. [Pharmacological aspects of therapeutic botulinum toxin preparations]. Nervenarzt 2006; 77:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roggenkämper P, Jost WH, Bihari K, et al. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm (Vienna) 2006; 113:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. Eur J Neurol 2009; 16 Suppl 2:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol 2009; 16 Suppl 2:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dressler D. Comparing Botox and Xeomin for axillar hyperhidrosis. J Neural Transm (Vienna) 2010; 117:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sattler G, Callander MJ, Grablowitz D, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg 2010; 36 Suppl 4:2146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prager W, Wissmüller E, Kollhorst B, et al. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study. Dermatol Surg 2010; 36 Suppl 4:2155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rzany BJ, Ascher B, Avelar RL, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients. Aesthet Surg J 2020; 40:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheon HI, Jung N, Won CH, et al. Efficacy and Safety of Prabotulinumtoxin A and Onabotulinumtoxin A for Crow's Feet: A Phase 3, Multicenter, Randomized, Double-Blind, Split-Face Study. Dermatol Surg 2019; 45:1610.
          </a>
         </li>
         <li class="breakAll">
          Allergan, Inc. Botox Cosmetic (botulinum toxin type A) purified neurotoxin complex (prescribing information). Allergan, Inc, Irvine, CA 2005.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feily A, Fallahi H, Zandian D, Kalantar H. A succinct review of botulinum toxin in dermatology; update of cosmetic and noncosmetic use. J Cosmet Dermatol 2011; 10:58.
          </a>
         </li>
         <li class="breakAll">
          Jeuveau (prabotulinumtoxinA-xvfs) for injection, for intramuscular use. US FDA approved product information; Santa Barbara, CA: Evolus Inc; February 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761085s000lbl.pdf (Accessed on June 11, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg 2003; 29:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 2004; 140:1351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu A, Carruthers A, Cohen JL, et al. Recommendations and current practices for the reconstitution and storage of botulinum toxin type A. J Am Acad Dermatol 2012; 67:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol 2002; 138:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen SB, Goldenberg NA. Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study. Dermatol Surg 2012; 38:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hexsel DM, De Almeida AT, Rutowitsch M, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg 2003; 29:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hui JI, Lee WW. Efficacy of fresh versus refrigerated botulinum toxin in the treatment of lateral periorbital rhytids. Ophthal Plast Reconstr Surg 2007; 23:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lizarralde M, Gutiérrez SH, Venegas A. Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines. Dermatol Surg 2007; 33:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang GC, Chiu RJ, Gillman GS. Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox. Arch Facial Plast Surg 2008; 10:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hexsel D, Brum C, do Prado DZ, et al. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial. J Am Acad Dermatol 2012; 67:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hexsel D, Dal'Forno T, Hexsel C, et al. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg 2008; 34:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg 2009; 35:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flynn TC. Advances in the use of botulinum neurotoxins in facial esthetics. J Cosmet Dermatol 2012; 11:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jandhyala R. Relative potency of incobotulinumtoxinA vs onabotulinumtoxinA a meta-analysis of key evidence. J Drugs Dermatol 2012; 11:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alam M, Geisler A, Sadhwani D, et al. Effect of Needle Size on Pain Perception in Patients Treated With Botulinum Toxin Type A Injections: A Randomized Clinical Trial. JAMA Dermatol 2015; 151:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giordano CN, Matarasso SL, Ozog DM. Injectable and topical neurotoxins in dermatology: Indications, adverse events, and controversies. J Am Acad Dermatol 2017; 76:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brin MF, Boodhoo TI, Pogoda JM, et al. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol 2009; 61:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004; 20:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coté TR, Mohan AK, Polder JA, et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005; 53:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeWitt PA, Trosch RM. Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection. Mov Disord 1997; 12:1064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li M, Goldberger BA, Hopkins C. Fatal case of BOTOX-related anaphylaxis? J Forensic Sci 2005; 50:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nong LB, He WQ, Xu YH, et al. [Severe respiratory failure after injection of botulinum toxin: case report and review of the literature]. Zhonghua Jie He He Hu Xi Za Zhi 2008; 31:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chertow DS, Tan ET, Maslanka SE, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006; 296:2476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology 2015; 95:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuehn BM. FDA requires black box warnings on labeling for botulinum toxin products. JAMA 2009; 301:2316.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. Information for health care professionals: onabotulinumtoxinA (marketed as Botox/Botox  Cosmetic), abobotulinumtoxinA (marketed as Dysport) and rimabotulinumtoxinB (marketed as Myobloc). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm (Accessed on March 28, 2011).
         </li>
         <li class="breakAll">
          Food and Drug Administration. Early communication about an ongoing safety review: Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B). 2008. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070366.htm (Accessed on July 02, 2010).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rzany B, Dill-Müller D, Grablowitz D, et al. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol Surg 2007; 33:S18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005; 20:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Defazio G, Abbruzzese G, Girlanda P, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002; 59:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen JL, Schlessinger J, Cox SE, et al. An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J 2009; 29:S43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monheit GD, Cohen JL, Reloxin Investigational Group. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol 2009; 61:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sattler G. Current and future botulinum neurotoxin type A preparations in aesthetics: a literature review. J Drugs Dermatol 2010; 9:1065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003; 60:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SK. Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. Dermatol Surg 2007; 33:S105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995; 45:1743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dressler D. New formulation of BOTOX. Complete antibody-induced therapy failure in hemifacial spasm. J Neurol 2004; 251:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dressler D, Wohlfahrt K, Meyer-Rogge E, et al. Antibody-induced failure of botulinum toxin a therapy in cosmetic indications. Dermatol Surg 2010; 36 Suppl 4:2182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord 2010; 25:2211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrence I, Moy R. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A. Aesthet Surg J 2009; 29:S66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers J, Burgess C, Day D, et al. Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and Energy-Based Devices. Dermatol Surg 2016; 42:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman KR, Carruthers J. Combination therapy with BOTOX and fillers: the new rejuvnation paradigm. Dermatol Ther 2006; 19:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fagien S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 1999; 103:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fagien S, Brandt FS. Primary and adjunctive use of botulinum toxin type A (Botox) in facial aesthetic surgery: beyond the glabella. Clin Plast Surg 2001; 28:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers J, Carruthers A, Maberley D. Deep resting glabellar rhytides respond to BTX-A and Hylan B. Dermatol Surg 2003; 29:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers J, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg 2003; 29:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel MP, Talmor M, Nolan WB. Botox and collagen for glabellar furrows: advantages of combination therapy. Ann Plast Surg 2004; 52:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carruthers A, Carruthers J, Monheit GD, et al. Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatol Surg 2010; 36 Suppl 4:2121.
          </a>
         </li>
         <li class="breakAll">
          Carruthers J, Carruthers A. Combining botulinum toxin injection and laser for facial rhytides. In: Skin Resurfacing, Coleman WP, Lawrence N (Eds), Williams and Wilkins, 1998. p.235.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worcester S. Use of Botox before and after laser facial resurfacing. Skin Allergy News 2000; 31:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimbler MS, Holds JB, Kokoska MS, et al. Effect of botulinum toxin pretreatment on laser resurfacing results: a prospective, randomized, blinded trial. Arch Facial Plast Surg 2001; 3:165.
          </a>
         </li>
         <li class="breakAll">
          Alster TS. Laser resurfacing of rhytides. In: Manual of Cutaneous Laser Techniques, Alster TS (Ed), Lippincott-Raven Publishers, 19997. p.104.
         </li>
         <li>
          <a class="nounderline abstract_t">
           West TB, Alster TS. Effect of botulinum toxin type A on movement-associated rhytides following CO2 laser resurfacing. Dermatol Surg 1999; 25:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamauchi PS, Lask G, Lowe NJ. Botulinum toxin type A gives adjunctive benefit to periorbital laser resurfacing. J Cosmet Laser Ther 2004; 6:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacGregor JL, Tanzi EL. Microfocused ultrasound for skin tightening. Semin Cutan Med Surg 2013; 32:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gassner HG, Sherris DA, Otley CC. Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg 2000; 105:1948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherris DA, Gassner HG. Botulinum toxin to minimize facial scarring. Facial Plast Surg 2002; 18:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gassner HG, Sherris DA. Chemoimmobilization: improving predictability in the treatment of facial scars. Plast Reconstr Surg 2003; 112:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gassner HG, Brissett AE, Otley CC, et al. Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study. Mayo Clin Proc 2006; 81:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson AM. Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg 2006; 117:1758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flynn TC. Use of intraoperative botulinum toxin in facial reconstruction. Dermatol Surg 2009; 35:182.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13643 Version 23.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : DasGupta BR. Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In: Therapy with Botulinum Toxin, Jankovic J, Hallet M (Eds), Marcel Dekker, 1994. p.15.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9167258" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Botulinum toxin: the story of its development for the treatment of human disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16558852" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Notes on Bacillus botulinus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11851731" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11851731" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7243198" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21161715" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3815164" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1448532" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4084867" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A pilot study on the use of botulinum toxin in spasmodic torticollis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1740562" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Treatment of glabellar frown lines with C. botulinum-A exotoxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11474747" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Botulinum toxin type A: history and current cosmetic use in the upper face.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15222575" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Botulinum toxin A in the mid and lower face and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15158540" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cosmetic uses of botulinum toxins for lower aspects of the face and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17317554" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Botulinum toxins for facial wrinkles: beyond glabellar lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19050545" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A comprehensive review of patient-reported satisfaction with botulinum toxin type a for aesthetic procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21134048" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : OnabotulinumtoxinA treatment of mild glabellar lines in repose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8357583" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Botulinum toxin for the treatment of hyperfunctional lines of the face.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28522038" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Injectable and topical neurotoxins in dermatology: Basic science, anatomy, and therapeutic agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11755789" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11755789" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17763029" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The evolution of botulinum neurotoxin type A for cosmetic applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17385940" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21209727" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21209727" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12075218" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12752520" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14504489" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12752518" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinkles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21134043" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20725542" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Topical botulinum toxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18491179" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Novel topical BoNTA (CosmeTox, toxin type A) cream used to treat hyperfunctional wrinkles of the face, mouth, and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18491179" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Novel topical BoNTA (CosmeTox, toxin type A) cream used to treat hyperfunctional wrinkles of the face, mouth, and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20369902" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Botulinum toxin: examining duration of effect in facial aesthetic applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20369902" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Botulinum toxin: examining duration of effect in facial aesthetic applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12063480" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12973229" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15841623" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19250310" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15871316" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27110893" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Duration of Clinical Efficacy of OnabotulinumtoxinA in Crow's Feet Lines: Results from Two Multicenter, Randomized, Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19537366" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19549186" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19584772" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19584772" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17241416" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12269875" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12752521" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30893162" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31609882" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12534505" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16336882" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A comparison of two botulinum type a toxin preparations for the treatment of glabellar lines: double-blind, randomized, pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12079632" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12789177" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Reduction in injection pain with botulinum toxin type B further diluted using saline with preservative: a double-blind, randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11909903" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14632812" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17241413" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18254812" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18608706" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20919448" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16810528" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : [Pharmacological aspects of therapeutic botulinum toxin preparations].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15959841" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20002739" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Routine use of Xeomin in patients previously treated with Botox: long term results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20002742" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20143241" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Comparing Botox and Xeomin for axillar hyperhidrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21134045" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21134046" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30951166" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30893169" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Efficacy and Safety of Prabotulinumtoxin A and Onabotulinumtoxin A for Crow's Feet: A Phase 3, Multicenter, Randomized, Double-Blind, Split-Face Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30893169" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Efficacy and Safety of Prabotulinumtoxin A and Onabotulinumtoxin A for Crow's Feet: A Phase 3, Multicenter, Randomized, Double-Blind, Split-Face Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21332916" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : A succinct review of botulinum toxin in dermatology; update of cosmetic and noncosmetic use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21332916" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : A succinct review of botulinum toxin in dermatology; update of cosmetic and noncosmetic use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12752527" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Complications, adverse reactions, and insights with the use of botulinum toxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15545544" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Effect of volume and concentration on the diffusion of botulinum exotoxin A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22055283" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Recommendations and current practices for the reconstitution and storage of botulinum toxin type A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11939813" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22268727" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12752522" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18030112" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Efficacy of fresh versus refrigerated botulinum toxin in the treatment of lateral periorbital rhytids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17958584" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18645097" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22041253" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18053050" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19018816" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22360334" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Advances in the use of botulinum neurotoxins in facial esthetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22648220" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Relative potency of incobotulinumtoxinA vs onabotulinumtoxinA a meta-analysis of key evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26352252" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effect of Needle Size on Pain Perception in Patients Treated With Botulinum Toxin Type A Injections: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28522039" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Injectable and topical neurotoxins in dermatology: Indications, adverse events, and controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19744746" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15265242" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Safety of botulinum toxin type A: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16112345" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9399239" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15831014" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Fatal case of BOTOX-related anaphylaxis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18953963" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : [Severe respiratory failure after injection of botulinum toxin: case report and review of the literature].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17119144" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25613637" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19509371" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : FDA requires black box warnings on labeling for botulinum toxin products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19509371" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : FDA requires black box warnings on labeling for botulinum toxin products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19509371" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : FDA requires black box warnings on labeling for botulinum toxin products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17241409" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15645481" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Long-term botulinum toxin efficacy, safety, and immunogenicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11890846" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19945004" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19577326" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20865836" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Current and future botulinum neurotoxin type A preparations in aesthetics: a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12682332" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17278332" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7675238" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Response and immunoresistance to botulinum toxin injections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15015023" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : New formulation of BOTOX. Complete antibody-induced therapy failure in hemifacial spasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21134050" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Antibody-induced failure of botulinum toxin a therapy in cosmetic indications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20737546" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19945007" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8196686" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Development of resistance to botulinum toxin type A in patients with torticollis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27100962" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and Energy-Based Devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16784517" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Combination therapy with BOTOX and fillers: the new rejuvnation paradigm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9950563" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11248863" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Primary and adjunctive use of botulinum toxin type A (Botox) in facial aesthetic surgery: beyond the glabella.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12752525" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Deep resting glabellar rhytides respond to BTX-A and Hylan B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12859378" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15096921" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Botox and collagen for glabellar furrows: advantages of combination therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21134044" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21134044" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Use of Botox before and after laser facial resurfacing
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11497500" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Effect of botulinum toxin pretreatment on laser resurfacing results: a prospective, randomized, blinded trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11497500" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Effect of botulinum toxin pretreatment on laser resurfacing results: a prospective, randomized, blinded trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10417577" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Effect of botulinum toxin type A on movement-associated rhytides following CO2 laser resurfacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15545098" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Botulinum toxin type A gives adjunctive benefit to periorbital laser resurfacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24049925" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Microfocused ultrasound for skin tightening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10839391" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11823931" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Botulinum toxin to minimize facial scarring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14504533" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Chemoimmobilization: improving predictability in the treatment of facial scars.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16901024" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16651948" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Use of botulinum toxin type A to prevent widening of facial scars.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19215253" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Use of intraoperative botulinum toxin in facial reconstruction.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
